give you a heads-up: the biotech sector doesn’t care how many shareholders lined up for selfies or autographs. Investor groupies clustering around a CEO doesn’t replace actual due diligence, nor does it offset cash burn, delays, and dilution and shattered share price.
ou want to talk about guest speakers and FDA meetings like that’s some sort of flex? Great. But those don’t pay bills. Revenue does. Execution does. Shareholder returns do. Mesoblast still has to prove it can deliver on any of that sustainably
Hope we could all pay bills, sip single malt, eat out, sponsor holidays by simply saying "my bio tech investment has FDA meetings and speakers all over it."
And that is the fact.
MSB Price at posting:
$1.73 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)